@soicfinance Most were bullish on #SeQuent a day before the annual results the other week. Most would have left the train in next few quarters due to ESOP led margin compression on P&L. Playing long innings like Rahul Dravid is not same as watching him play :)

@RemindMe_OfThis in 200 days

More from Sajal Kapoor

More from Pharma

Indian Pharma Dream 11 Q-compliance ranking: (1st Edition July 2021)
1.Natco (Captain)
2.Neuland (Vice-Captain)
3. Alkem (WB)
4.Cipla(Team coach)
5. Lupin
6. Laurus
7. Hikal
8.Cadila
9.Sun
10.Alembic
11. Unichem
12.Torrent
13. DRL
14. Strides
15.Wockhardt
Investors review tip👇


a) Whenever any major regulatory inspection happens at mfg sites of:
a) #1 to #7, remain fully assured of a success
b)#8 to #13, read Hanuman chalisaa or any sacred book as per faith every day till the inspection lasts.
c) #14 and #15 sell ur position and pick anyone of Dream 11

You May Also Like

"I lied about my basic beliefs in order to keep a prestigious job. Now that it will be zero-cost to me, I have a few things to say."


We know that elite institutions like the one Flier was in (partial) charge of rely on irrelevant status markers like private school education, whiteness, legacy, and ability to charm an old white guy at an interview.

Harvard's discriminatory policies are becoming increasingly well known, across the political spectrum (see, e.g., the recent lawsuit on discrimination against East Asian applications.)

It's refreshing to hear a senior administrator admits to personally opposing policies that attempt to remedy these basic flaws. These are flaws that harm his institution's ability to do cutting-edge research and to serve the public.

Harvard is being eclipsed by institutions that have different ideas about how to run a 21st Century institution. Stanford, for one; the UC system; the "public Ivys".